In a sterile, high-tech manufacturing facility in Raritan, New Jersey, a profound intersection of humanity and biotechnology recently took place. Colleen, a patient who had battled multiple myeloma—a relentless blood cancer—walked through the doors of the facility where Legend Biotech and Johnson & Johnson produce Carvykti, the life-saving CAR-T cell therapy that had returned her to health.
For the employees who spend their days meticulously engineering cellular products, this was more than a corporate visit; it was a visceral reminder of the "why" behind their work. In the world of personalized medicine, a commercial dose is not a standardized pill produced by the millions in a factory hopper. It is a bespoke biological intervention, meticulously crafted for one person, derived from their own cells, and returned to their body to fight a singular battle.
This meeting underscored the unique operating model of modern cell therapy: a reality where the "product" is inextricably linked to the patient’s identity. As the commercial footprint of therapies like Carvykti expands, the industry faces a daunting paradox: how to scale a process that is, by definition, inherently individual.
The Evolution of CAR-T: From Clinical Novelty to Commercial Mainstay
The rise of CAR-T (Chimeric Antigen Receptor T-cell) therapy represents one of the most significant shifts in modern oncology. Since the first approvals in 2017, the field has moved from academic curiosity to a robust commercial sector.
A Brief Chronology of Progress:
- 2017: The FDA grants the first-ever approval for a CAR-T therapy, signaling a paradigm shift in how we treat refractory blood cancers.
- 2022: Legend Biotech and J&J secure approval for Carvykti. The therapy begins its ascent, quickly becoming a standard of care for relapsed or refractory multiple myeloma.
- 2024–2025: The "scaling out" phase accelerates. Manufacturers shift from small-scale clinical batches to large-scale, multi-site commercial production.
- June 2025: In a landmark regulatory move, the FDA eliminates restrictive Risk Evaluation and Mitigation Strategies (REMS) for several CAR-T therapies, including Carvykti, acknowledging the increased safety data and aiming to improve access for patients in rural and community settings.
This progression has been nothing short of exponential. Carvykti, in particular, has seen massive commercial traction, reporting $657 million in second-quarter net trade sales in 2026—a 50% increase over the previous year. Today, the treatment is available at 348 sites across 19 global markets, yet this success brings the industry to a critical crossroads: the limitation of "scaling out" versus "scaling up."
The Manufacturing Challenge: Why "Scaling Out" is Harder Than "Scaling Up"
In traditional pharmaceutical manufacturing, scaling is a matter of volume. If a company needs more tablets, they build larger bioreactors or utilize bigger mixing vats. In the world of autologous cell therapy—where a patient’s own T-cells are harvested, genetically reprogrammed, and re-infused—you cannot simply increase the size of the batch.
"When you scale an autologous cell therapy, you don’t scale up, you scale out," explains Mike O’Mara, Chief Operating Officer of Cellipont Bioservices.
The Logistics of the Individual
"Scaling out" means replicating a highly complex, labor-intensive process thousands of times simultaneously, without allowing for variability. In early clinical trials, a small, tight-knit team of scientists can manage a handful of patients. But as volume grows to support thousands of patients annually, the manufacturing process must become a rigid, automated, and highly reproducible industrial machine.
Every single dose requires a perfect alignment of:
- Patient-Specific Logistics: Tracking the patient’s cells from the treatment center to the lab and back.
- Manufacturing Slots: Coordinating specific production windows that match clinical treatment schedules.
- Quality Assurance: Rigorous testing of each batch to ensure sterility, potency, and identity.
- Supply Chain Stability: Sourcing raw materials that meet strict clinical standards, often amidst global shortages.
"The real question is not simply, ‘Can we manufacture another batch?’" O’Mara notes. "It is, ‘Can we manufacture it, test it, release it, and deliver it consistently within the required timeframe?’"
Strategic Infrastructure: Building the Global Backbone
Legend Biotech has spent years constructing a global infrastructure designed to minimize the risk of bottlenecks. The company’s strategy centers on a regionalized manufacturing model: utilizing U.S.-based facilities for U.S. patients and European facilities for international markets.
This footprint includes the expanded Raritan facility, a contract manufacturing partnership with Novartis in Morris Plains, New Jersey, and the Obelisc and Tech Lane facilities in Ghent, Belgium. By decentralizing production, Legend minimizes the risks associated with long-distance shipping and ensures that a failure in one geographic region does not jeopardize the entire global supply chain.
The Metrics of Reliability
The results of this investment are measurable. Legend has reported a 99% manufacturing success rate—a staggering figure given the complexity of the process. Furthermore, the company has achieved a 29-day median turnaround time in the U.S., with over 95% of products delivered on time. These metrics are not merely operational; they are central to the commercial proposition. For a cancer patient, the difference of a few days in the manufacturing pipeline can be the difference between a successful intervention and disease progression.
Overcoming Downstream and Upstream Friction
While the manufacturing process is the heart of the operation, the body of the therapy extends far into the hospital system. The "two-way dependency" between treatment centers and manufacturers remains a critical challenge.
If a hospital cancels a procedure or a patient’s health fluctuates, a reserved manufacturing slot can be left empty, effectively wasting millions of dollars in potential capacity. Conversely, if the manufacturing process experiences a delay, the patient’s clinical window for treatment may close.
Regulatory Streamlining
The recent FDA decision to eliminate REMS requirements is a major step toward mitigating these frictions. By shortening the mandatory monitoring periods and allowing for more outpatient administration, the FDA is helping to decentralize care. This allows patients to receive treatment in their local communities rather than traveling to specialized, high-volume academic centers, thereby reducing the logistical burden on the patient and the healthcare system.
Lessons for Future Developers: Design for Scale
A common misconception among early-stage biotech companies is that manufacturing optimization is a "phase three problem." According to industry experts like O’Mara, this is a recipe for failure.
"The most common misconception is that there will always be time later to optimize the manufacturing process," O’Mara warns. Decisions made in the laboratory—such as the choice of a specific raw material, a manual cell-washing step, or a slow analytical assay—can become insurmountable operational bottlenecks once the company moves to commercial volume.
The industry is now seeing a significant shift: manufacturability is being treated with the same weight as safety and efficacy. Companies are increasingly moving toward standardized commercial platforms, leveraging automation and closed-processing systems to reduce operator-to-operator variability.
The Next Frontier: Moving Toward In Vivo CAR-T
While the current autologous model is a medical triumph, its manufacturing burden is undeniably high. The future of the industry may lie in removing the "ex vivo" (outside the body) portion of the chain entirely.
Legend Biotech is among the pioneers exploring in vivo CAR-T options. The concept is revolutionary: instead of extracting, modifying, and re-infusing cells, a gene vector is injected directly into the patient to modify immune cells inside the body.
Legend’s early-stage candidate, LB2501, is currently being tested for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Early proof-of-concept data from 12 patients has shown that the therapy can work as intended without significant toxicities.
If successful, this approach would fundamentally change the scaling model. Instead of an individualized, one-off manufacturing run for every patient, the company would produce a standardized vector. While this would still require high-quality manufacturing, it would remove the most volatile and labor-intensive parts of the autologous chain, potentially allowing for a faster, cheaper, and more scalable treatment profile.
Conclusion: The Path Ahead
The story of Carvykti is, in many ways, the story of the 21st-century biotech industry. It is a story of moving from the "heroic" era of medicine—where miraculous treatments were limited to a few—to an industrial era where those miracles are delivered at scale to the thousands.
As Legend Biotech and its peers navigate the complexities of cell therapy, they are not just building products; they are building systems. They are learning that the "manufacturing process" is not a separate entity from the science—it is the science. Whether through the meticulous industrialization of autologous processes or the potential breakthrough of in vivo therapies, the industry is proving that when it comes to saving lives, the logistics of hope are just as critical as the molecules themselves.
As Mike O’Mara aptly summarizes, the goal is to create systems flexible enough to support innovation while being rigid enough to deliver consistency. For patients like Colleen, the precision of these manufacturing systems isn’t just an operational achievement—it is the lifeline that allows them to return to the world they almost lost.
About the Author
